← Human Trials & Peer-Reviewed Studies
Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition.
Plain-language guide to PMID 9039333 (1996): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 9039333
- Journal
- Clinical endocrinology
- Year
- 1996
- Study type
- Randomized Controlled Trial
- Authors
- Jørgensen JO et al. (6 authors)
- DOI
- 10.1046/j.1365-2265.1996.8720883.x
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
Studies with GH substitution in GH-deficient (GHD) adults lasting more than 6 months have so far been uncontrolled.
End-points such as physical fitness and body composition may be subject to a considerable placebo effect which weakens the validity of open studies.
Who Took Part
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
For body composition measurements a control group of 39 healthy, age and sex-matched subjects was included.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.
Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.
Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.
The Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group ran side by side rather than switching.
What Was Measured
The subject headings attached to it are Abdomen, Adipose Tissue, Body Composition, Exercise Tolerance, Growth Disorders, Growth Hormone and Human Growth Hormone.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Results are reported in around 12 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 1996 (Clinical endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.